Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by compound 3, and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.

Abstract: The present invention provides a humanized anti-TPBG antibody, a preparation method therefor, a conjugate thereof, and applications. The humanized anti-TPBG antibody comprises: (a), a framework region comprising a residue of a human antibody framework region; and (b) one or more CDRs of a light-chain variable region as shown in the SEQ ID NO:4 or 8 or one or more CDRs of a heavy-chain variable region as shown in the SEQ ID NO:2 or 6.

Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by formula (1), and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.

Abstract: Disclosed in the present invention are a peptide compound, an application thereof, and a composition containing the same. Provided in the present invention are a peptide compound represented by formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a solvate thereof, a crystal form thereof, or a prodrug thereof. The compound has good stability and good activity.

Abstract: The present invention provides a TPBG antibody, a preparation method thereof, conjugates and use thereof. The TPBG antibody comprises one or more of the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 of the heavy chain variable region of TPBG antibody, and/or one or more of the light chain CDR1, the light chain CDR2 and the light chain CDR3 of the light chain variable region of TPBG antibody, and the amino acid sequences of which are described in the present invention. The TPBG antibody is humanized antibody with high affinity, and the conjugates prepared by coupling the TPBG antibody with the small-molecule drug toxin MMAF can have a cytotoxicity effects on TPBG-positive cells, therefore the TPBG antibody can be used in the preparation of drugs for treating tumors and the like.

Abstract: Disclosed are an EGFRvIII antibody and a conjugate, and a preparation method and the use thereof. The antibody comprises complementarity-determining regions (CDRs) of the EGFRvIII antibody: one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3, and/or one or more of light chain CDR1, light chain CDR2 and light chain CDR3, with the amino acid sequence thereof being as described in the present invention. The EGFRvIII antibody has a high affinity with the EGFRvIII protein, and can enter cells after coupling with small molecule toxins such as MMAE and has a cytotoxic killing effect on EGFRvIII positive cells. The antibody therefore can be used for preparing drugs for treating tumors and other diseases.

Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by formula (1), and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.

Abstract: The present invention provides a humanized anti-TPBG antibody, a preparation method therefor, a conjugate thereof, and applications. The humanized anti-TPBG antibody comprises: (a), a framework region comprising a residue of a human antibody framework region; and (b) one or more CDRs of a light-chain variable region as shown in the SEQ ID NO:4 or 8 or one or more CDRs of a heavy-chain variable region as shown in the SEQ ID NO:2 or 6.

Abstract: Disclosed are an antibody drug conjugate IB, which uses ether linkages for connection, and improves the water solubility, stability and cytotoxicity in vivo and in intro, and an intermediate, a pharmaceutical composition, and uses of the antibody drug conjugate. The antibody drug conjugate has simple synthetic steps and a high yield.

Abstract: Disclosed are an antibody drug conjugate IB, which uses ether linkages for connection, and improves the water solubility, stability and cytotoxicity in vivo and in intro, and an intermediate, a pharmaceutical composition, and uses of the antibody drug conjugate. The antibody drug conjugate has simple synthetic steps and a high yield.